EC
ORIC icon

Euclidean Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Euclidean Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Hold
989,410
– – 2.44% 4
2026
Q1 		$12.5M Hold
989,410
– – 3.2% 4
2025
Q4 		$8.09M Hold
989,410
– – 2.19% 5
2025
Q3 		$11.9M Hold
989,410
– – 4.99% 3
2025
Q2 		$10M Hold
989,410
– – 3.28% 3
2025
Q1 		$5.52M Hold
989,410
– – 2.07% 4
2024
Q4 		$7.98M Hold
989,410
– – 1.08% 4
2024
Q3 		$10.1M Hold
989,410
– – 1.12% 5
2024
Q2 		$7M Hold
989,410
– – 0.88% 4
2024
Q1 		$13.6M Hold
989,410
– – 1.74% 4
2023
Q4 		$9.1M Hold
989,410
– – 1.02% 8
2023
Q3 		$5.99M Buy
989,410
+241,860
+32% +$1.98M 1.31% 9
2023
Q2 		$5.8M Hold
747,550
– – 1.49% 9
2023
Q1 		$4.26M Hold
747,550
– – 3.74% 7
2022
Q4 		$4.4M Hold
747,550
– – 4.12% 7
2022
Q3 		$2.39M Hold
747,550
– – 2.22% 9
2022
Q2 		$3.35M Hold
747,550
– – 2.85% 9
2022
Q1 		$3.99M Hold
747,550
– – 2.32% 10
2021
Q4 		$11M Sell
747,550
-29,643
-4% -$462K 6.25% 7
2021
Q3 		$16.3M Sell
777,193
-219,541
-22% -$4.45M 7.9% 7
2021
Q2 		$17.6M Hold
996,734
– – 5.72% 7
2021
Q1 		$24.4M Sell
996,734
-403,701
-29% -$12.8M 8.17% 3
2020
Q4 		$47.4M Buy
+1,400,435
New +$40.2M 10.04% 3

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Euclidean Capital's ORIC Position: Q2 2026 in Review

Euclidean Capital held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 989,410 shares worth $10.7M. The position accounts for 2.44% of the portfolio, ranked #4.

Euclidean Capital first reported a position in ORIC in Q4 2020 and has held it in 23 quarters since. The position peaked at $47.4M in Q4 2020. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Euclidean Capital held 989,410 shares of Oric Pharmaceuticals worth $10.7M as of Q2 2026.
  • Euclidean Capital left its Oric Pharmaceuticals share count unchanged in Q2 2026.
  • Oric Pharmaceuticals made up 2.44% of Euclidean Capital's portfolio in Q2 2026, its #4 holding.
  • Euclidean Capital first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Euclidean Capital's Oric Pharmaceuticals position peaked at $47.4M in Q4 2020.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Euclidean Capital's 13F filing for Q2 2026, filed 14 Aug 2026.